The following database contains a listing of drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Drug information typically includes the drug name, approval status, indication of use, and clinical trial results. Review descriptions for our medical therapeutic area list to help assist in your search.Join our Drug Research Updates group on LinkedIn!
Cardiology/Vascular Diseases
Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) ; FoldRx Pharmaceuticals; For the treatment of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis, Approved May 2019
Dental and Oral Health
Otezla (apremilast); Celgene; For the treatment of adults with oral ulcers associated with Behçet’s Disease, Approved July 2019
Dermatology
Duobrii (halobetasol propionate and tazarotene) ; Ortho Dermatologics; For the treatment of plaque psoriasis , Approved April 2019
Jeuveau (prabotulinumtoxinA-xvfs); Evolus; For the improvement of glabellar lines, Approved February 2019
Skyrizi (risankizumab-rzaa) ; AbbVie; For the treatment of plaque psoriasis, Approved April 2019
Endocrinology
Jatenzo (testosterone undecanoate); Clarus Therapeutics; For the treatment of male conditions associated with a deficiency or absence of endogenous testosterone , Approved March 2019
Family Medicine
Tosymra (sumatriptan) nasal spray; Dr. Reddy’s Labs; For the treatment of acute migraine in adults, Approved January 2019
Gastroenterology
Keytruda (pembrolizumab) ; Merck; For the treatment of recurrent esophageal cancer with PD-L1 expressing tumors , Approved July 2019
Recarbrio (imipenem, cilastatin, and relebactam); Merck; For the treatment of complicated intra-abdominal and urinary tract infections, Approved July 2019
Genetic Disease
Esperoct [antihemophilic factor (recombinant), glycopegylated-exei]; Novo Nordisk; For the treatment of hemophilia A, Approved February 2019
Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) ; FoldRx Pharmaceuticals; For the treatment of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis, Approved May 2019
Zolgensma (onasemnogene abeparvovec-xioi) ; Avexis; For the treatment of pediatrics <2 years of age with spinal muscular atrophy with bi-allelic mutations in the SMN1 gene, Approved May 2019
Hematology
Cablivi (caplacizumab-yhdp); Ablynx; For the treatment of acquired thrombotic thrombocytopenic purpura, Approved February 2019
Esperoct [antihemophilic factor (recombinant), glycopegylated-exei]; Novo Nordisk; For the treatment of hemophilia A, Approved February 2019
Inrebic (fedratinib); Celgene; For the treatment of myelofibrosis, Approved August 2019
Polivy (polatuzumab vedotin-piiq) ; Genentech; For the treatment of diffuse large B-cell lymphoma, Approved June 2019
Venclexta (venetoclax) plus Gazyva (obinutuzumab); Genentech and AbbVie; For the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma , Approved May 2019
Xpovio (selinexor) ; Karyopharm Therapeutics; For the treatment of adults with relapsed or refractory multiple myeloma , Approved July 2019
Hepatology (Liver, Pancreatic, Gall Bladder)
Cyramza (ramucirumab) ; Eli Lilly; For the treatment of hepatocellular carcinoma with elevated alpha-fetoprotein (AFP), Approved May 2019
Egaten (triclabendazole); Novartis; For the treatment of fascioliasis (liver fluke infestation), Approved February 2019
Immunology
Asceniv (Immune Globulin Intravenous, Human – slra 10% Liquid); ADMA Biologics; For the treatment of Primary Humoral Immunodeficiency Disease , Approved April 2019
Dovato (dolutegravir and lamivudine) ; ViiV Healthcare; For the treatment of HIV-1 infection in adults, Approved April 2019
Otezla (apremilast); Celgene; For the treatment of adults with oral ulcers associated with Behçet’s Disease, Approved July 2019
Ruzurgi (amifampridine); Jacobus Pharmaceuticals; For the treatment of Lambert-Eaton myasthenic syndrome in pediatrics, Approved May 2019
Infections and Infectious Diseases
Dengvaxia (Dengue Tetravalent Vaccine, Live) ; sanofi pasteur; For the prevention of dengue disease, Approved May 2019
Dovato (dolutegravir and lamivudine) ; ViiV Healthcare; For the treatment of HIV-1 infection in adults, Approved April 2019
Egaten (triclabendazole); Novartis; For the treatment of fascioliasis (liver fluke infestation), Approved February 2019
Jakafi (ruxolitinib); Incyte; For the treatment of steroid-refractory acute graft-versus-host disease in adults and pediatrics >12 years , Approved May 2019
Pretomanid tablets; TB Alliance; For the treatment of adults with drug resistant tuberculosis, Approved August 2019
Recarbrio (imipenem, cilastatin, and relebactam); Merck; For the treatment of complicated intra-abdominal and urinary tract infections, Approved July 2019
Xenleta (lefamulin) ; Nabriva Therapeutics; For the treatment of community acquired bacterial pneumonia, Approved August 2019
Musculoskeletal
Cimzia (certolizumab pegol); UCB; For the treatment of non-radiographic axial spondyloarthritis, Approved March 2019
Evenity (romosozumab-aqqg); Amgen; For the treatment of osteoporosis in postmenopausal women at high risk for fracture, Approved April 2019
Mavenclad (cladribine) ; Merck; For the treatment of relapsing multiple sclerosis, Approved March 2019
Mayzent (siponimod); Novartis; For the treatment of relapsing multiple sclerosis, Approved March 2019
Rinvoq (upadacitinib); AbbVie; For the treatment of rheumatoid arthritis, Approved August 2019
Ruzurgi (amifampridine); Jacobus Pharmaceuticals; For the treatment of Lambert-Eaton myasthenic syndrome in pediatrics, Approved May 2019
Zolgensma (onasemnogene abeparvovec-xioi) ; Avexis; For the treatment of pediatrics <2 years of age with spinal muscular atrophy with bi-allelic mutations in the SMN1 gene, Approved May 2019
Nephrology
Bavencio (avelumab) plus Inlyta (axitinib) ; Merck and Pfizer; For the first line treatment of advanced renal cell carcinoma, Approved May 2019
Keytruda (pembrolizumab); Merck; For the treatment of advanced renal cell carcinoma, Approved April 2019
Neurology
Wakix (pitolisant) ; Bioprojet Pharma; For the treatment of excessive daytime sleepiness in adults with narcolepsy , Approved August 2019
Mavenclad (cladribine) ; Merck; For the treatment of relapsing multiple sclerosis, Approved March 2019
Mayzent (siponimod); Novartis; For the treatment of relapsing multiple sclerosis, Approved March 2019
Nayzilam (midazolam); UCB; For the treatment of intermittent, stereotypic episodes of frequent seizure activity, Approved May 2019
Ruzurgi (amifampridine); Jacobus Pharmaceuticals; For the treatment of Lambert-Eaton myasthenic syndrome in pediatrics, Approved May 2019
Spravato (esketamine) nasal spray; Janssen Pharmaceuticals; For the treatment of treatment-resistant depression in adults, Approved March 2019
Sunosi (solriamfetol) ; Jazz Pharmaceuticals; For the treatment of excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea, Approved March 2019
Tosymra (sumatriptan) nasal spray; Dr. Reddy’s Labs; For the treatment of acute migraine in adults, Approved January 2019
Obstetrics/Gynecology (Women’s Health)
Evenity (romosozumab-aqqg); Amgen; For the treatment of osteoporosis in postmenopausal women at high risk for fracture, Approved April 2019
Herceptin Hylecta (trastuzumab and hyaluronidase-oysk); Halozyme; For the treatment of HER2-overexpressing breast cancer, Approved February 2019
Piqray (alpelisib) ; Novartis; For the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer, Approved May 2019
Tecentriq (atezolizumab); Genentech/Roche; For the treatment of triple negative breast cancer, Approved March 2019
Vyleesi (bremelanotide injection); AMAG Pharmaceuticals; For the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder, Approved June 2019
Zulresso (brexanolone); Sage Therapeutics; For the treatment of postpartum depression, Approved March 2019
Oncology
Balversa (erdafitinib); Janssen Oncology; For the treatment of locally advanced or metastatic urothelial carcinoma , Approved April 2019
Bavencio (avelumab) plus Inlyta (axitinib) ; Merck and Pfizer; For the first line treatment of advanced renal cell carcinoma, Approved May 2019
Cyramza (ramucirumab) ; Eli Lilly; For the treatment of hepatocellular carcinoma with elevated alpha-fetoprotein (AFP), Approved May 2019
Herceptin Hylecta (trastuzumab and hyaluronidase-oysk); Halozyme; For the treatment of HER2-overexpressing breast cancer, Approved February 2019
Inrebic (fedratinib); Celgene; For the treatment of myelofibrosis, Approved August 2019
Keytruda (pembrolizumab) ; Merck; For the treatment of recurrent esophageal cancer with PD-L1 expressing tumors , Approved July 2019
Keytruda (pembrolizumab); Merck; previously treated metastatic small cell lung cancer, Approved June 2019
Keytruda (pembrolizumab); Merck; For the treatment of advanced renal cell carcinoma, Approved April 2019
Keytruda (pembrolizumab); Merck; For the treatment of stage III non-small cell lung cancer, Approved April 2019
Nubeqa (darolutamide); Bayer; For the treatment of non-metastatic castration-resistant prostate cancer, Approved July 2019
Piqray (alpelisib) ; Novartis; For the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer, Approved May 2019
Polivy (polatuzumab vedotin-piiq) ; Genentech; For the treatment of diffuse large B-cell lymphoma, Approved June 2019
Rozlytrek (entrectinib); Genentech; For the treatment of ROS1-positive non-small cell lung cancer and NTRK Gene Fusion-Positive Solid Tumors, Approved August 2019
Tecentriq (atezolizumab); Genentech/Roche; For the treatment of extensive-stage small cell lung cancer , Approved March 2019
Tecentriq (atezolizumab); Genentech/Roche; For the treatment of triple negative breast cancer, Approved March 2019
Turalio (pexidartinib); Daiichi Sankyo; For the treatment of symptomatic tenosynovial giant cell tumor, Approved August 2019
Venclexta (venetoclax) plus Gazyva (obinutuzumab); Genentech and AbbVie; For the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma , Approved May 2019
Xpovio (selinexor) ; Karyopharm Therapeutics; For the treatment of adults with relapsed or refractory multiple myeloma , Approved July 2019
Ophthalmology
Rocklatan (netarsudil and latanoprost ophthalmic solution); Aerie Pharmaceuticals; For the treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, Approved March 2019
Otolaryngology (Ear, Nose, Throat)
Dupixent (dupilumab); Regeneron Pharmaceuticals and Sanofi; For the treatment of chronic rhinosinusitis with nasal polyposis in adults , Approved June 2019
Keytruda (pembrolizumab) ; Merck; For the treatment of recurrent esophageal cancer with PD-L1 expressing tumors , Approved July 2019
Pediatrics/Neonatology
Nayzilam (midazolam); UCB; For the treatment of intermittent, stereotypic episodes of frequent seizure activity, Approved May 2019
Ruzurgi (amifampridine); Jacobus Pharmaceuticals; For the treatment of Lambert-Eaton myasthenic syndrome in pediatrics, Approved May 2019
Zolgensma (onasemnogene abeparvovec-xioi) ; Avexis; For the treatment of pediatrics <2 years of age with spinal muscular atrophy with bi-allelic mutations in the SMN1 gene, Approved May 2019
Psychiatry/Psychology
Spravato (esketamine) nasal spray; Janssen Pharmaceuticals; For the treatment of treatment-resistant depression in adults, Approved March 2019
Zulresso (brexanolone); Sage Therapeutics; For the treatment of postpartum depression, Approved March 2019
Pulmonary/Respiratory Diseases
Duaklir Pressair (aclidinium bromide and formoterol fumarate) ; Circassia Pharmaceuticals; For the maintenance treatment of chronic obstructive pulmonary disease, Approved April 2019
Keytruda (pembrolizumab); Merck; For the treatment of stage III non-small cell lung cancer, Approved April 2019
Keytruda (pembrolizumab); Merck; previously treated metastatic small cell lung cancer, Approved June 2019
Pretomanid tablets; TB Alliance; For the treatment of adults with drug resistant tuberculosis, Approved August 2019
Rozlytrek (entrectinib); Genentech; For the treatment of ROS1-positive non-small cell lung cancer and NTRK Gene Fusion-Positive Solid Tumors, Approved August 2019
Sunosi (solriamfetol) ; Jazz Pharmaceuticals; For the treatment of excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea, Approved March 2019
Tecentriq (atezolizumab); Genentech/Roche; For the treatment of extensive-stage small cell lung cancer , Approved March 2019
Xenleta (lefamulin) ; Nabriva Therapeutics; For the treatment of community acquired bacterial pneumonia, Approved August 2019
Rare Diseases and Disorders
Otezla (apremilast); Celgene; For the treatment of adults with oral ulcers associated with Behçet’s Disease, Approved July 2019
Rheumatology
Cimzia (certolizumab pegol); UCB; For the treatment of non-radiographic axial spondyloarthritis, Approved March 2019
Rinvoq (upadacitinib); AbbVie; For the treatment of rheumatoid arthritis, Approved August 2019
Urology
Balversa (erdafitinib); Janssen Oncology; For the treatment of locally advanced or metastatic urothelial carcinoma , Approved April 2019
Jatenzo (testosterone undecanoate); Clarus Therapeutics; For the treatment of male conditions associated with a deficiency or absence of endogenous testosterone , Approved March 2019
Nubeqa (darolutamide); Bayer; For the treatment of non-metastatic castration-resistant prostate cancer, Approved July 2019
Recarbrio (imipenem, cilastatin, and relebactam); Merck; For the treatment of complicated intra-abdominal and urinary tract infections, Approved July 2019
Vaccines
Dengvaxia (Dengue Tetravalent Vaccine, Live) ; sanofi pasteur; For the prevention of dengue disease, Approved May 2019
Post a Comment